摘要
目的探讨瑞格列奈联合阿卡波糖对2型糖尿病患者糖脂代谢及胰岛素抵抗的影响。方法选取2020年8月~2022年8月在中国人民解放军第九六〇医院接受治疗的110例2型糖尿病患者作为研究对象,按照随机数字表法将其分成对照组与观察组,各55例。对照组予以瑞格列奈治疗,观察组在对照组基础上联合阿卡波糖治疗,比较两组治疗前后的血糖指标、血脂指标、胰岛功能指标和治疗效果。结果治疗后两组空腹血糖(FPG)、餐后两小时血糖(2 hPG)、糖化血红蛋白(HbA1c)、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C),胰岛素抵抗指数(HOMA-IR)水平均较治疗前下降,高密度脂蛋白胆固醇(HDL-C)、胰岛β细胞功能指数(HOMA-β)水平均上升,且观察组变化幅度比对照组更明显(P<0.05)。观察组治疗总有效率为94.55%,高于对照组的81.82%(P<0.05)。结论瑞格列奈与阿卡波糖联合治疗2型糖尿病患者效果确切,有助于改善糖脂代谢,降低胰岛素抵抗程度。
Objective To investigate the effects of repaglinide combined with acarbose on glucose and lipid metabolism and insulin resistance in patients with type 2 diabetes mellitus.Methods A total of 110 patients with type 2 diabetes who received treatment in the NO.960 Hospital of the Chinese People's Liberation Army from August 2020 to August 2022 were selected as research objects.According to the random number table method,they were divided into control group and observation group,55 cases in each group.The control group was treated with repaglinide,and the observation group was treated with acarbose on the basis of the control group.Blood glucose indexes,blood lipid indexes,islet function indexes and therapeutic effects of the two groups were compared before and after treatment.Results After treatment,the levels of FPG,2 hPG,HbA1c,TC,TG,LDL-C and HOMA-IR in both groups were decreased compared with before treatment,while the levels of HDL-C and HOMA-βwere increased,and the change range of observation group was more obvious than control group(P<0.05).The total effective rate of the observation group was 94.55%,which was higher than that of the control group(81.82%,P<0.05).Conclusion The combination of repaglinide and acarbose is effective in the treatment of type 2 diabetes patients,which can help to improve glycolipid metabolism and reduce the degree of insulin resistance.
作者
徐芹
周璐
XU Qin;ZHOU Lu(Department of pharmacy,No.960 Hospital of PLA,Jinan 250000,China;不详)
出处
《中国处方药》
2023年第7期125-128,共4页
Journal of China Prescription Drug
